Litigation Details for Akebia Therapeutics, Inc. v. Azar (D. Mass. 2019)
✉ Email this page to a colleague
Akebia Therapeutics, Inc. v. Azar (D. Mass. 2019)
Docket | ⤷ Try a Trial | Date Filed | 2019-10-15 |
Court | District Court, D. Massachusetts | Date Terminated | 2021-10-26 |
Cause | 05:702 Administrative Procedure Act | Assigned To | Allison Dale Burroughs |
Jury Demand | None | Referred To | |
Patents | 10,300,039; 7,767,851; 8,093,423; 8,299,298; 8,338,642; 8,609,896; 8,754,257; 8,754,258; 8,846,976; 8,901,349; 9,050,316; 9,328,133; 9,387,191; 9,757,416 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Akebia Therapeutics, Inc. v. Azar
Details for Akebia Therapeutics, Inc. v. Azar (D. Mass. 2019)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-10-15 | 1 | 9,328,133; 9,757,416; 9,387,191; and 10,300,039. These patents include compound claims directed to the…is covered by a number of patents. Akebia is the sub-licensee of U.S. Patent No. 5,753,706, claiming therapeutic…manner. Akebia holds a patent on the process of manufacturing Auryxia. See U.S. Patent No. No. 6,903,235.…the plain meaning of the statute. Auryxia is a patented drug product consisting of a complex synthetic…not listed on the FRF. III. THE DEVELOPMENT, PATENTING, AND FDA APPROVAL OF AURYXIA 25. | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |